Literature DB >> 17666094

Determination of glutamic acid decarboxylase antibodies (GADA) IgG subclasses - comparison of three immunoprecipitation assays (IPAs).

M Hillman1, C Törn, M Landin-Olsson.   

Abstract

IgG subclasses of glutamic acid decarboxylase (GAD(65)) antibodies (GADA) may reflect the immunological state in the pancreas of GADA-positive patients with autoimmune diabetes. The use of biotin-conjugated antibodies and streptavidin Sepharose are used commonly in immunoprecipitation assays (IPA) based on (125)I- or (35)S-labelled antigens to capture IgG subclasses directed against IA-2 or GAD(65). We have compared three different immunoprecipitation assays for the determination of GADA IgG subclasses. Two of the assays were based on the biotin and streptavidin systems provided in a solid (immobilized) or liquid (mobilized) phase binding environment. The third assay was based on N-hydroxysuccinimide (immobilized) interaction with primary amines (i.e. lysine residues) on the antibody. We found the liquid phase binding assay (LPBA) to be the most stable assay, with a comparatively low coefficient of variation and background.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17666094      PMCID: PMC2219287          DOI: 10.1111/j.1365-2249.2007.03473.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  17 in total

Review 1.  Statistical techniques for comparing measurers and methods of measurement: a critical review.

Authors:  John Ludbrook
Journal:  Clin Exp Pharmacol Physiol       Date:  2002-07       Impact factor: 2.557

Review 2.  Autoantibodies in diabetes.

Authors:  Catherine Pihoker; Lisa K Gilliam; Christiane S Hampe; Ake Lernmark
Journal:  Diabetes       Date:  2005-12       Impact factor: 9.461

3.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

4.  IA-2 autoantibodies restricted to the IgG4 subclass are associated with protection from type 1 diabetes.

Authors:  J Seissler; K Eikamp; M Schott; W A Scherbaum
Journal:  Horm Metab Res       Date:  2002-04       Impact factor: 2.936

5.  Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.

Authors:  C Törn; M Landin-Olsson; J Ostman; B Scherstén; H Arnqvist; G Blohmé; E Björk; J Bolinder; J Eriksson; B Littorin; L Nyström; G Sundkvist; A Lernmark
Journal:  Diabetes Metab Res Rev       Date:  2000 Nov-Dec       Impact factor: 4.876

6.  Diabetes Antibody Standardization Program: first assay proficiency evaluation.

Authors:  Polly J Bingley; Ezio Bonifacio; Patricia W Mueller
Journal:  Diabetes       Date:  2003-05       Impact factor: 9.461

7.  Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: isotype restriction and polyclonality.

Authors:  M I Hawa; D Fava; F Medici; Y J Deng; A L Notkins; G De Mattia; R D Leslie
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

Review 8.  A two-signal model for regulation of immunoglobulin isotype switching.

Authors:  J Purkerson; P Isakson
Journal:  FASEB J       Date:  1992-11       Impact factor: 5.191

9.  A novel radioligand binding assay to determine diagnostic accuracy of isoform-specific glutamic acid decarboxylase antibodies in childhood IDDM.

Authors:  C E Grubin; T Daniels; B Toivola; M Landin-Olsson; W A Hagopian; L Li; A E Karlsen; E Boel; B Michelsen; A Lernmark
Journal:  Diabetologia       Date:  1994-04       Impact factor: 10.122

10.  Human B cell clones can be induced to proliferate and to switch to IgE and IgG4 synthesis by interleukin 4 and a signal provided by activated CD4+ T cell clones.

Authors:  H Gascan; J F Gauchat; M G Roncarolo; H Yssel; H Spits; J E de Vries
Journal:  J Exp Med       Date:  1991-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.